CN1348362A - 磁响应组合物 - Google Patents

磁响应组合物 Download PDF

Info

Publication number
CN1348362A
CN1348362A CN99803728A CN99803728A CN1348362A CN 1348362 A CN1348362 A CN 1348362A CN 99803728 A CN99803728 A CN 99803728A CN 99803728 A CN99803728 A CN 99803728A CN 1348362 A CN1348362 A CN 1348362A
Authority
CN
China
Prior art keywords
compositions
carbon
ferrum
granule
weight ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99803728A
Other languages
English (en)
Chinese (zh)
Inventor
V·A·沃尔孔斯基
S·D·久克舍尔斯特诺夫
S·V·切尔尼亚科夫
L·M·阿伦
T·B·肯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FeRx Inc
Original Assignee
FeRx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FeRx Inc filed Critical FeRx Inc
Publication of CN1348362A publication Critical patent/CN1348362A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN99803728A 1998-01-06 1999-01-06 磁响应组合物 Pending CN1348362A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/003,286 US6200547B1 (en) 1994-01-26 1998-01-06 Magnetically responsive compositions for carrying biologically active substances and methods of production and use

Publications (1)

Publication Number Publication Date
CN1348362A true CN1348362A (zh) 2002-05-08

Family

ID=21705076

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99803728A Pending CN1348362A (zh) 1998-01-06 1999-01-06 磁响应组合物

Country Status (11)

Country Link
US (1) US6200547B1 (https=)
EP (1) EP1043975A4 (https=)
JP (1) JP2002500177A (https=)
KR (1) KR20010024836A (https=)
CN (1) CN1348362A (https=)
AU (1) AU744205B2 (https=)
BR (1) BR9906786A (https=)
CA (1) CA2317019C (https=)
IL (2) IL137033A0 (https=)
NZ (1) NZ505408A (https=)
WO (1) WO1999034779A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015520A1 (fr) * 2004-08-11 2006-02-16 Yangde Zhang Procédé de préparation de nanoparticules magnétiques de galactosyle-has contenant de l’adriamycine
CN100384475C (zh) * 2002-10-29 2008-04-30 德州科隆载体研究所 磁引导抗癌药剂的制备方法

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482436B1 (en) * 1993-01-29 2002-11-19 Ferx Incorporated Magnetically responsive composition
ATE510855T1 (de) * 2000-03-06 2011-06-15 Univ Kentucky Res Found Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen
US6488615B1 (en) 2000-03-31 2002-12-03 Ferx Incorporated Permanent magnet keeper-shield assembly
US7090636B2 (en) * 2000-03-31 2006-08-15 Fe Rx Incorporated Permanent magnet keeper-shield assembly
US7863011B2 (en) * 2000-05-10 2011-01-04 Signe Biopharma, Inc. Screening method for predicting susceptibility to breast cancer
US20030072812A1 (en) 2001-05-10 2003-04-17 Sirbasku David A Breast cancer eradication program
MXPA02011092A (es) 2000-05-10 2004-08-19 David A Sirbasku Composiciones y metodos para demostrar la regulacion del sistema inmune secretor del crecimiento de la celula de cancer que responde a la hormona esteroidea.
US8119138B2 (en) * 2000-05-10 2012-02-21 Signe Biopharma Inc. Anti-estrogen and immune modulator combinations for treating breast cancer
US6921283B2 (en) * 2001-08-27 2005-07-26 Trompeter Electronics, Inc. BNC connector having visual indication
US6679827B2 (en) * 2001-10-11 2004-01-20 Robert E. Sandstrom Magnetic field enhancement of tumor treatment
EP1530720A4 (en) * 2001-11-13 2005-08-31 David A Sirbasku PROGRAM FOR EXPLOITING BREAST CANCER
US7249604B1 (en) 2002-05-10 2007-07-31 Vasmo, Inc. Medical devices for occlusion of blood flow
US20040133099A1 (en) * 2002-12-18 2004-07-08 Dyer R. Kent Otologic nanotechnology
US20050261763A1 (en) * 2003-04-08 2005-11-24 Xingwu Wang Medical device
US20050155779A1 (en) * 2003-04-08 2005-07-21 Xingwu Wang Coated substrate assembly
US20050025797A1 (en) * 2003-04-08 2005-02-03 Xingwu Wang Medical device with low magnetic susceptibility
US20050244337A1 (en) * 2003-04-08 2005-11-03 Xingwu Wang Medical device with a marker
US20050240100A1 (en) * 2003-04-08 2005-10-27 Xingwu Wang MRI imageable medical device
US20050278020A1 (en) * 2003-04-08 2005-12-15 Xingwu Wang Medical device
US8651113B2 (en) * 2003-06-18 2014-02-18 Swr&D Inc. Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
US7344491B1 (en) 2003-11-26 2008-03-18 Nanobiomagnetics, Inc. Method and apparatus for improving hearing
US7723311B2 (en) * 2003-06-18 2010-05-25 Nanobiomagnetics, Inc. Delivery of bioactive substances to target cells
DE10359252A1 (de) * 2003-12-17 2005-07-28 Siemens Ag Navigierte Wärmebehandlung von Tumoren mit enzymumhüllten Eisenpartikeln
US20070027532A1 (en) * 2003-12-22 2007-02-01 Xingwu Wang Medical device
US7846201B2 (en) * 2004-02-20 2010-12-07 The Children's Hospital Of Philadelphia Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
US8562505B2 (en) * 2004-02-20 2013-10-22 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US9028829B2 (en) * 2004-02-20 2015-05-12 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US20070100457A1 (en) * 2004-03-04 2007-05-03 Hyde Edward R Jr Paramagnetic liquid interface
GB0405552D0 (en) * 2004-03-12 2004-04-21 Magnet Attraction Ltd Methods for the targetted delivery of biological molecules
US20070231393A1 (en) * 2004-05-19 2007-10-04 University Of South Carolina System and Device for Magnetic Drug Targeting with Magnetic Drug Carrier Particles
US20080124400A1 (en) * 2004-06-24 2008-05-29 Angiotech International Ag Microparticles With High Loadings Of A Bioactive Agent
WO2007035871A1 (en) * 2005-09-21 2007-03-29 Massachusetts Institute Of Technology Systems and methods for tuning properties of nanoparticles
US20070255086A1 (en) * 2006-04-26 2007-11-01 Nehls Robert J Medical Device Including Magnetic Particles
WO2008127735A1 (en) 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
EP2205225A4 (en) * 2007-10-03 2013-09-18 Jncasr Bangalore INTRINSIC FLUORESCENCE CARBON NANOSPHERES AND PROCESS FOR PRODUCING THE SAME
US20090169484A1 (en) 2007-12-28 2009-07-02 Ihi Corporation Iron-salen complex
JP2009274962A (ja) * 2008-05-12 2009-11-26 Yoshihiro Ishikawa 鉄サレン錯体、磁性を有する薬剤、薬剤の誘導システム、並びに磁気検出装置
JP5513405B2 (ja) 2008-11-20 2014-06-04 株式会社Ｉｈｉ 自己磁性金属サレン錯体化合物
US10398668B2 (en) 2010-10-19 2019-09-03 The Board Of Regents Of The University Of Oklahoma Glutamate treatment of cardiovascular disorders
US8740872B2 (en) 2010-10-19 2014-06-03 The Board Of Regents Of The University Of Oklahoma Magnetically-targeted treatment for cardiac disorders
US9744235B2 (en) 2010-10-19 2017-08-29 The Board Of Regents Of The University Of Oklahoma Treatment of cardiovascular disorders with targeted nanoparticles
JP2012176905A (ja) * 2011-02-25 2012-09-13 Ihi Corp 金属サレン錯体化合物
CN103517895A (zh) 2010-12-21 2014-01-15 株式会社Ihi 金属沙仑配位化合物及其制造方法
WO2022034176A2 (en) * 2020-08-13 2022-02-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Delivery device
WO2025118073A1 (en) * 2023-12-04 2025-06-12 Rocket Science Health Corp. Magnetic formulations for biomarker sampling and enhanced drug delivery

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3718594A (en) 1970-11-30 1973-02-27 Eastman Kodak Co Method of preparing magnetically responsive carrier particles
US4106488A (en) 1974-08-20 1978-08-15 Robert Thomas Gordon Cancer treatment method
US4247406A (en) 1979-04-23 1981-01-27 Widder Kenneth J Intravascularly-administrable, magnetically-localizable biodegradable carrier
US4345588A (en) 1979-04-23 1982-08-24 Northwestern University Method of delivering a therapeutic agent to a target capillary bed
US4331654A (en) 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
WO1983001738A1 (en) 1981-11-12 1983-05-26 SCHRÖDER, Ulf Intravascularly administrable, magnetically responsive nanosphere or manoparticle, a process for the production thereof, and the use thereof
US4652257A (en) 1985-03-21 1987-03-24 The United States Of America As Represented By The Secretary Of The Navy Magnetically-localizable, polymerized lipid vesicles and method of disrupting same
US4849209A (en) 1985-06-07 1989-07-18 Cadema Medical Products, Inc. Treatment of arthritis, including rheumatoid arthritis with 166 Holmium radionuclide
US4818614A (en) 1985-07-29 1989-04-04 Shiseido Company Ltd. Modified powder
US4690130A (en) 1985-12-19 1987-09-01 Mirell Stuart G Electromagnetic therapy control system
US4871716A (en) 1986-02-04 1989-10-03 University Of Florida Magnetically responsive, hydrophilic microspheres for incorporation of therapeutic substances and methods of preparation thereof
JPH01122037U (https=) 1988-02-12 1989-08-18
SU1722256A3 (ru) 1989-11-02 1992-03-23 Viktor A Volkonskij Cпocoб пoлучehия maгhиtoупpabляemoй диcпepcии
ES2165385T3 (es) 1993-01-29 2002-03-16 Ferx Inc Composicion sensible al campo magnetico para transportar sustancias biologicamente activas y metodos de produccion y utilizacion.
US5776925A (en) * 1996-01-25 1998-07-07 Pharmacyclics, Inc. Methods for cancer chemosensitization
US5827533A (en) * 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100384475C (zh) * 2002-10-29 2008-04-30 德州科隆载体研究所 磁引导抗癌药剂的制备方法
WO2006015520A1 (fr) * 2004-08-11 2006-02-16 Yangde Zhang Procédé de préparation de nanoparticules magnétiques de galactosyle-has contenant de l’adriamycine

Also Published As

Publication number Publication date
AU744205B2 (en) 2002-02-21
CA2317019C (en) 2003-10-14
IL137033A (en) 2005-12-18
EP1043975A4 (en) 2007-05-02
EP1043975A1 (en) 2000-10-18
NZ505408A (en) 2003-04-29
AU2027999A (en) 1999-07-26
IL137033A0 (en) 2001-06-14
WO1999034779A1 (en) 1999-07-15
US6200547B1 (en) 2001-03-13
JP2002500177A (ja) 2002-01-08
BR9906786A (pt) 2000-10-17
KR20010024836A (ko) 2001-03-26
CA2317019A1 (en) 1999-07-15

Similar Documents

Publication Publication Date Title
CN1348362A (zh) 磁响应组合物
US6482436B1 (en) Magnetically responsive composition
EP2624846A2 (en) Nanoparticle-loaded cells
JP2010516705A (ja) 温熱療法におけるサセプタとその使用法
Sharma et al. The role of functionalized magnetic iron oxide nanoparticles in the central nervous system injury and repair: new potentials for neuroprotection with Cerebrolysin therapy
Peng et al. Hollow mesoporous tantalum oxide based nanospheres for triple sensitization of radiotherapy
Han et al. Spatiotemporal tracking of gold nanorods after intranasal administration for brain targeting
Tung et al. One-stop radiotherapeutic targeting of primary and distant osteosarcoma to inhibit cancer progression and metastasis using 2DG-grafted graphene quantum dots
JP2003512336A (ja) 磁気標的化キャリア
JP7431940B2 (ja) 腫瘍を治療するための方法
TWI487528B (zh) 醫藥組成物在製備檢測癌細胞是否具有放射抗性之藥物之用途、醫藥組成物在製備提升癌細胞之放射敏感性的藥物之用途、及癌細胞放射抗性之檢測方法
Varshosaz et al. Encapsulation of imatinib in targeted KIT-5 nanoparticles for reducing its cardiotoxicity and hepatotoxicity
Xu et al. Macrophage reprogramming combined with enhanced photodynamic therapy increases the patency of malignant esophageal obstruction after stenting
CN108992418A (zh) 药物组合物、制备方法及其用途
Yakovlev et al. Detonation nanodiamonds as promising drug carriers
KR102698260B1 (ko) 산화철 자성 입자를 포함하는 간암치료용 조성물
CN1976681A (zh) 可磁性靶向丝裂霉素c组合物及其使用方法
KR102681399B1 (ko) 산화철 자성 입자를 포함하는 간암치료용 조성물의 제조방법
US20200138984A1 (en) Superparamagnetic gold nanoparticle cluster-protein nanoparticle hybrid for magnetic resonance imaging and magnetic hyperthermia
Pham et al. 153 Sm-labeled Fe 3 O 4@ lapatinib nanoparticles as a potential therapeutic agent for breast cancer: synthesis, quality control, and in vivo evaluation
US20170119914A1 (en) Nanoparticles and method for manufacturing the same
EP4157457A1 (en) Nanoparticles, ionizing radiation and innovative therapeutic combinations thereof
EP4591890A1 (en) Lipid nanoparticle for radiation therapy, manufacturing method, combination composition, and kit
Zeinizade et al. Atomically-precise Au
MXPA00006625A (en) Magnetically responsive composition

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication